Nantkwest (NK) Stock Rating Lowered by BidaskClub
BidaskClub lowered shares of Nantkwest (NASDAQ:NK) from a sell rating to a strong sell rating in a report issued on Friday morning.
NK has been the topic of several other research reports. Zacks Investment Research raised shares of Nantkwest from a hold rating to a buy rating and set a $5.75 price target on the stock in a research report on Wednesday, October 11th. Raymond James Financial reaffirmed a hold rating on shares of Nantkwest in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company. The stock presently has an average rating of Hold and a consensus target price of $5.25.
Nantkwest (NASDAQ:NK) traded down $0.01 during mid-day trading on Friday, hitting $4.37. 175,300 shares of the stock traded hands, compared to its average volume of 226,085. The stock has a market cap of $369.07 and a price-to-earnings ratio of -3.70. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. Nantkwest has a 1 year low of $2.71 and a 1 year high of $8.45.
WARNING: This article was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/nantkwest-nk-stock-rating-lowered-by-bidaskclub/1818411.html.
NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.